Market Overview:
The global kidney cancer treatment drugs market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of kidney cancer, rising awareness about available treatments, and technological advancements in the field of oncology. The global kidney cancer treatment drugs market is segmented on the basis of type into angiogenesis inhibitors, mTOR inhibitors, monoclonal antibodies, and cytokine immunotherapy (IL-2). The angiogenesis inhibitors segment is expected to dominate the market during the forecast period owing to their high efficacy and growing adoption for treating various types of cancers. On the basis of application, hospitals are expected to account for a major share of the global kidney cancer treatment drugs market duringthe forecast period. This can be attributedto th egrowing numberof patients with renal cell carcinoma (RCC) seeking hospital-based careand increasing availabilityof advancedtreatment optionsin these settings. Research institutes are also anticipatedtobe a keyapplication area forkidneycancer treatmentsdrugs due t othe growing demandfor earlystage drug developmentand clinical trials servicesfor newtherapiesinthe fieldofoncology .
Product Definition:
Kidney cancer treatment drugs are used to treat kidney cancer. The importance of these drugs is that they can help to stop the spread of the cancer and improve the patient's prognosis.
Angiogenesis Inhibitors:
The angiogenesis inhibitors market is expected to witness lucrative growth over the forecast period owing to its ability to impede the growth of new blood vessels that supply oxygen-rich blood to tumors. Angiogenesis inhibitors are used in kidney cancer treatment as they slow down or block tumor growth by hindering the formation of new blood vessels that feed oxygen and other nutrients into a tumor.
mTOR Inhibitors:
TOR (target of Rapamycin) inhibitors are a type of drug that works by decreasing the activity of mTOR, which is a kinase enzyme responsible for cell growth. TOR inhibitors have been used in clinical trials for treatment against renal cancer. The main driver associated with the growth of this market is its potential use as an immunotherapy agent and hence it can be used to treat patients who cannot receive radiation therapy or whose disease has progressed after undergoing radiation therapy.
Application Insights:
The market is segmented into hospitals, research institutes, diagnostic centers and others. Hospitals held the largest share in 2017 owing to availability of advanced healthcare facilities and services at major cities across the globe. The presence of a large patient base with different types of cancer requiring kidney cancer treatment drugs for their management further drives the hospital segment.
Research Institutes are anticipated to be one of the fastest-growing segments over forecast period due to increasing government funding for oncology research coupled with rising number of R&D initiatives undertaken by various companies including Pfizer, Merck & Co., Inc., Amgen Inc., Novartis AG and sanofi aventis among others. These initiatives are aimed at discovering new molecules that can be used as potential drug therapies against different forms of kidney cancers thus augmenting growth prospects over forecast period.
Regional Analysis:
North America dominated the global kidney cancer treatment drugs market in 2017. This can be attributed to the presence of key players, availability of effective treatments, high healthcare expenditure and awareness about early diagnosis. In addition, government initiatives for increasing R&D investments to develop novel therapies are expected to fuel growth during the forecast period. For instance, in May 2018; ‘NIH’s Roadmap Epigenetics Research Program’ was launched by NIH which is aimed at exploring epigenetic factors involved in a number of diseases including kidney cancer as well as their role in health and disease progression (U.S.).
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to rising disposable income leading towards an increase in healthcare spending along with improving access due to rising medical tourism especially from emerging economies such as India & China & Japan etc.; these factors are expected favorably impact market dynamics during the forecast period.
Growth Factors:
- Increasing incidence of kidney cancer
- Growing demand for better and advanced kidney cancer treatment drugs
- Rising awareness about kidney cancer and its treatment options
- Technological advancements in the field of drug development for kidney cancer treatment
- Availability of government funding for research on new drugs for the treatment of kidney cancer
Scope Of The Report
Report Attributes
Report Details
Report Title
Kidney Cancer Treatment Drugs Market Research Report
By Type
Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies, Cytokine Immunotherapy (IL-2)
By Application
Hospitals, Research Institutes, Diagnostic Centers, Others
By Companies
Amgen/Allergan, Argos Therapeutics, AstraZeneca, Aveo Pharmaceuticals, Bayer, Exelixis, Incyte, Merck, Roche, Pfizer, Amgen/Allergan, Eisai, Prometheus Labs, Novartis
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
213
Number of Tables & Figures
150
Customization Available
Yes, the report can be customized as per your need.
Global Kidney Cancer Treatment Drugs Market Report Segments:
The global Kidney Cancer Treatment Drugs market is segmented on the basis of:
Types
Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies, Cytokine Immunotherapy (IL-2)
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Research Institutes, Diagnostic Centers, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Amgen/Allergan
- Argos Therapeutics
- AstraZeneca
- Aveo Pharmaceuticals
- Bayer
- Exelixis
- Incyte
- Merck
- Roche
- Pfizer
- Amgen/Allergan
- Eisai
- Prometheus Labs
- Novartis
Highlights of The Kidney Cancer Treatment Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Angiogenesis Inhibitors
- mTOR Inhibitors
- Monoclonal Antibodies
- Cytokine Immunotherapy (IL-2)
- By Application:
- Hospitals
- Research Institutes
- Diagnostic Centers
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Kidney Cancer Treatment Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
There are many different types of cancer treatment drugs. Some chemotherapy drugs help to kill cancer cells by damaging their DNA. Other drugs help to shrink or block tumors from growing larger.
Some of the major players in the kidney cancer treatment drugs market are Amgen/Allergan, Argos Therapeutics, AstraZeneca, Aveo Pharmaceuticals, Bayer, Exelixis, Incyte, Merck, Roche, Pfizer, Amgen/Allergan, Eisai, Prometheus Labs, Novartis.
The kidney cancer treatment drugs market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Kidney Cancer Treatment Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Kidney Cancer Treatment Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Kidney Cancer Treatment Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Kidney Cancer Treatment Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Kidney Cancer Treatment Drugs Market Size & Forecast, 2018-2028
4.5.1 Kidney Cancer Treatment Drugs Market Size and Y-o-Y Growth
4.5.2 Kidney Cancer Treatment Drugs Market Absolute $ Opportunity
Chapter 5 Global Kidney Cancer Treatment Drugs Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Kidney Cancer Treatment Drugs Market Size Forecast by Type
5.2.1 Angiogenesis Inhibitors
5.2.2 mTOR Inhibitors
5.2.3 Monoclonal Antibodies
5.2.4 Cytokine Immunotherapy (IL-2)
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Kidney Cancer Treatment Drugs Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Kidney Cancer Treatment Drugs Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Research Institutes
6.2.3 Diagnostic Centers
6.2.4 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Kidney Cancer Treatment Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Kidney Cancer Treatment Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Kidney Cancer Treatment Drugs Analysis and Forecast
9.1 Introduction
9.2 North America Kidney Cancer Treatment Drugs Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Kidney Cancer Treatment Drugs Market Size Forecast by Type
9.6.1 Angiogenesis Inhibitors
9.6.2 mTOR Inhibitors
9.6.3 Monoclonal Antibodies
9.6.4 Cytokine Immunotherapy (IL-2)
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Kidney Cancer Treatment Drugs Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Research Institutes
9.10.3 Diagnostic Centers
9.10.4 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Kidney Cancer Treatment Drugs Analysis and Forecast
10.1 Introduction
10.2 Europe Kidney Cancer Treatment Drugs Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Kidney Cancer Treatment Drugs Market Size Forecast by Type
10.6.1 Angiogenesis Inhibitors
10.6.2 mTOR Inhibitors
10.6.3 Monoclonal Antibodies
10.6.4 Cytokine Immunotherapy (IL-2)
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Kidney Cancer Treatment Drugs Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Research Institutes
10.10.3 Diagnostic Centers
10.10.4 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Kidney Cancer Treatment Drugs Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Kidney Cancer Treatment Drugs Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Kidney Cancer Treatment Drugs Market Size Forecast by Type
11.6.1 Angiogenesis Inhibitors
11.6.2 mTOR Inhibitors
11.6.3 Monoclonal Antibodies
11.6.4 Cytokine Immunotherapy (IL-2)
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Kidney Cancer Treatment Drugs Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Research Institutes
11.10.3 Diagnostic Centers
11.10.4 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Kidney Cancer Treatment Drugs Analysis and Forecast
12.1 Introduction
12.2 Latin America Kidney Cancer Treatment Drugs Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Kidney Cancer Treatment Drugs Market Size Forecast by Type
12.6.1 Angiogenesis Inhibitors
12.6.2 mTOR Inhibitors
12.6.3 Monoclonal Antibodies
12.6.4 Cytokine Immunotherapy (IL-2)
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Kidney Cancer Treatment Drugs Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Research Institutes
12.10.3 Diagnostic Centers
12.10.4 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Kidney Cancer Treatment Drugs Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Kidney Cancer Treatment Drugs Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Kidney Cancer Treatment Drugs Market Size Forecast by Type
13.6.1 Angiogenesis Inhibitors
13.6.2 mTOR Inhibitors
13.6.3 Monoclonal Antibodies
13.6.4 Cytokine Immunotherapy (IL-2)
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Kidney Cancer Treatment Drugs Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Research Institutes
13.10.3 Diagnostic Centers
13.10.4 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Kidney Cancer Treatment Drugs Market: Competitive Dashboard
14.2 Global Kidney Cancer Treatment Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Amgen/Allergan
14.3.2 Argos Therapeutics
14.3.3 AstraZeneca
14.3.4 Aveo Pharmaceuticals
14.3.5 Bayer
14.3.6 Exelixis
14.3.7 Incyte
14.3.8 Merck
14.3.9 Roche
14.3.10 Pfizer
14.3.11 Amgen/Allergan
14.3.12 Eisai
14.3.13 Prometheus Labs
14.3.14 Novartis
